Cannabis Relieved IBD Symptoms but Was Linked to Higher Surgery Risk in Crohn's Disease
Among 313 IBD patients, cannabis users reported substantial symptom relief but those who used cannabis for over 6 months had 5 times the odds of requiring surgery for Crohn's disease.
Quick Facts
What This Study Found
Of 313 IBD patients surveyed, 17.6% had used cannabis specifically to treat their IBD symptoms, primarily through inhalation (96.4%). These patients reported notable subjective improvements: 83.9% said cannabis improved abdominal pain, 76.8% reported improved cramping, 48.2% noted improved joint pain, and 28.6% reported improved diarrhea.
However, the key finding was in outcomes: cannabis use for more than 6 months for IBD symptoms was a strong independent predictor of requiring surgery in Crohn's disease patients (OR = 5.03, 95% CI: 1.45-17.46), even after controlling for demographics, tobacco smoking, time since diagnosis, and biologic medication use.
Cannabis use was not a predictor of IBD-related hospitalization in the previous year.
Key Numbers
313 IBD patients. 17.6% used cannabis for IBD. Symptom improvement: pain 83.9%, cramping 76.8%, joint pain 48.2%, diarrhea 28.6%. Cannabis >6 months: OR 5.03 for surgery in Crohn's (95% CI: 1.45-17.46).
How They Did This
This was a cross-sectional study of 313 consecutive IBD patients seen at the University of Calgary from July 2008 to March 2009. Patients completed a structured anonymous questionnaire covering cannabis use patterns, motivations, and perceived effects. Logistic regression identified predictors of poor outcomes (surgery, hospitalization).
Why This Research Matters
This study highlights a critical disconnect between subjective symptom relief and objective disease outcomes. Cannabis may effectively reduce pain and cramping while the underlying disease continues to progress, potentially leading patients to delay or avoid treatments that could prevent the need for surgery.
The Bigger Picture
The paradox of symptom relief combined with worse disease outcomes is a critical consideration for IBD patients and their physicians. Cannabis may be masking disease activity while patients feel better, potentially delaying interventions that could prevent complications. This does not necessarily mean cannabis caused the worse outcomes, but the association demands caution.
What This Study Doesn't Tell Us
This was a cross-sectional study with self-reported data. The association between cannabis use and surgery could reflect confounding by disease severity: patients with more severe disease may be more likely to both use cannabis for symptom relief and eventually require surgery. Cannabis use patterns were not standardized. The sample was from a single center.
Questions This Raises
- ?Does cannabis mask disease activity in IBD, leading patients to undertreat their condition?
- ?Would combining cannabis with appropriate medical therapy avoid the surgery risk?
- ?Is the association causal or does it reflect disease severity?
Trust & Context
- Key Stat:
- 5x higher odds of surgery in Crohn's patients who used cannabis for >6 months (OR=5.03)
- Evidence Grade:
- This is a cross-sectional survey with regression analysis. The surgery association is notable but cannot prove causation due to potential confounding by disease severity.
- Study Age:
- Published in 2014. Research on cannabis and IBD outcomes continues with more controlled study designs.
- Original Title:
- Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease.
- Published In:
- Inflammatory bowel diseases, 20(3), 472-80 (2014)
- Authors:
- Storr, Martin(5), Devlin, Shane, Kaplan, Gilaad G(2), Panaccione, Remo, Andrews, Christopher N
- Database ID:
- RTHC-00869
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Does this mean cannabis is harmful for Crohn's disease?
Not necessarily. The association with surgery could mean cannabis users had more severe disease to begin with, leading them to both use cannabis and eventually need surgery. However, it raises the concern that symptom relief from cannabis might mask ongoing disease activity.
Should IBD patients avoid cannabis?
The authors caution that patients should be aware of potential harm until clinical trials clarify efficacy and safety. If cannabis is used, it should not replace standard medical therapy, and disease monitoring should continue regardless of symptom improvement.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-arthritis-research
Cite This Study
https://rethinkthc.com/research/RTHC-00869APA
Storr, Martin; Devlin, Shane; Kaplan, Gilaad G; Panaccione, Remo; Andrews, Christopher N. (2014). Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease.. Inflammatory bowel diseases, 20(3), 472-80. https://doi.org/10.1097/01.MIB.0000440982.79036.d6
MLA
Storr, Martin, et al. "Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease.." Inflammatory bowel diseases, 2014. https://doi.org/10.1097/01.MIB.0000440982.79036.d6
RethinkTHC
RethinkTHC Research Database. "Cannabis use provides symptom relief in patients with inflam..." RTHC-00869. Retrieved from https://rethinkthc.com/research/storr-2014-cannabis-use-provides-symptom
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.